FOLH1 and neoplasm: Gafita et al. [13] in their recent comparative study utilised the semi-automated qPSMA software [14] for tumour volume quantification, yielding also a significant increased risk of death for RECIP-PD patients undergoing 177Lu-PSMA radioligand therapy (HR = 4.33 (2.80–6.70), p < 0.001) that is again similar to our results.